DMAC
$3.39
Diamedica Therapeutics
$.11
3.35%
DMAC
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.19)
Revenue:  N/A
Tuesday
Aug 17
4:30 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when DMAC reports earnings?
Beat
Meet
Miss

Where is DMAC's stock price going from here?
Up
Flat
Down
Stock chart of DMAC
Analysts
Summary of analysts' recommendations for DMAC
Score
Grade
Pivots
Resistance
$3.49
$3.42
$3.35

$3.29

Support
$3.22
$3.15
$3.08
Tweet
Growth
Description
DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota.